Sector News

Allergan plots 117 job cuts in the wake of Kythera buyout

October 14, 2015
Life sciences

The job-cutting ax has been hovering over Kythera Biopharmaceuticals ever since Allergan agreed to buy the company in April. Now, that ax is getting ready to fall.

According to a notice filed with the state of California, Kythera will lay off 117 employees at its Westlake Village, CA, headquarters as of Nov. 30. The cuts include top Kythera executives–including CFO, CMO and chief commercial officer–and lower-level employees across the company, from HR and operations to R&D and manufacturing. Allergan closed on its purchase of the company on Oct. 1.

The layoffs amount to more than half of Kythera’s work force as of June 30, the Los Angeles Business Journal reports. In a second-quarter filing with the Securities and Exchange Commission, the company said it had 218 employees.

Merger-related layoffs aren’t uncommon, and soon after the deal was announced, Allergan said it would be cutting jobs at Kythera as it integrated the company into its own operations. CEO Brent Saunders said at the time that Allergan would keep “the vast majority” of the deal target’s employees.

Though some high-level sales and marketing managers will lose their jobs, including the chief commercial officer and the VP for U.S. sales, Allergan has said it would keep much of the sales force intact. Kythera is in the midst of a product rollout–the double-chin injection Kybella–and Allergan has high hopes for that launch.

Kybella could not only be a major product in itself, but could also add oomph to the rest of Allergan’s aesthetic product line, partly via cross-selling, and partly as an entry-level product for men. “Keep in mind, we don’t plan on eliminating any sales reps,” Saunders said when the deal was announced, adding that Allergan planned to “integrate the Kythera reps after closing into our sales force.”

The Westlake job cuts follow more than 1,000 for Allergan in California over the past year, first as the company fought off a buyout by Valeant Pharmaceuticals ($VRX), and then after its merger with Actavis.

By Tracy Staton

Source: Fierce Pharma

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach